← FDA DRUG APPROVALS

FDA ANDA · ANDA091589

TOBRAMYCIN

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA091589
TYPE
ANDA
ORIGINAL APPROVAL
2013-10-10
LATEST ACTION
2024-01-29
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

TOBRAMYCINPrescription
TOBRAMYCIN 300MG/5ML · SOLUTION · INHALATION

Approval history

2024-01-29Labeling · Supplement 12 · standardAP
2020-02-06Labeling · Supplement 10 · standardAP
2020-02-06Labeling · Supplement 9 · standardAP
2016-10-12Labeling · Supplement 5 · standardAP
2016-10-12Manufacturing (CMC) · Supplement 6AP
2015-09-01Labeling · Supplement 4 · standardAP
2013-10-10OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →